SOX/XELOX
Phase 2Small molecule
SOX/XELOX is one of 57 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
181 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Avastin
RochePhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Cyramza
Eli LillyPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lynparza
AstraZenecaPhase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric Cancer2 trials
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06564298·39 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SOX/XELOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- XXiangdong Cheng